Skip to content

A study to evaluate the efficacy and safety of weakly alkaline negatively potential single-molecule highly active water (AEMW) in improving comorbidities in patients undergoing chemotherapy for tumors

A study to evaluate the efficacy and safety of weakly alkaline negatively potential single-molecule highly active water (AEMW) in improving comorbidities in patients undergoing chemotherapy for tumors

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600122512
Enrollment
Unknown
Registered
2026-04-14
Start date
2026-04-14
Completion date
Unknown
Last updated
2026-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, high blood sugar, high uric acid, fatigue, insomnia, constipation

Interventions

Research group:Weakly alkaline negatively potential single-molecule highly active water intake
Control group:Take a placebo (pure water)

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Diagnosed with a malignant solid tumor and receiving anti-tumor treatments such as chemotherapy; 2. At least one of the following conditions: hypertension, hyperglycemia, hyperuricemia, fatigue, insomnia, constipation; (1). Hypertension: 1). The blood pressure is at a normal high value (130-139 MMHG for systolic pressure or 80-89 MMHG for diastolic pressure); 2) Patients with hypertension (systolic blood pressure >=140mmHg or diastolic blood pressure >=90mmHg) have unsatisfactory blood pressure control; (2) Hyperglycemia: 1) Prediabetes (fasting blood glucose >=6.1mmol/L, =5.7mmol/L, =7.0mmol/L or glycated hemoglobin >=6.5mmol/L) with unsatisfactory blood glucose control; (3) Hyperuricemia: Fasting blood uric acid in men and postmenopausal women > 420µmol/L (7 mg/dL), and in non-postmenopausal women >=360µmol/L (6 mg/dL); (4) Fatigue: Brief Fatigue Scale: >=1 point, that is, those with mild or severe fatigue; (5) Insomnia 1) The patient has sleep problems such as difficulty falling asleep, difficulty maintaining sleep or early awakening; 2) Accompanied by daytime functional disorders such as fatigue and inattention; 3) Simple improper sleep opportunities (insufficient time for sleep) or improper environment (the environment is not safe, dark, quiet and comfortable) cannot explain the reported sleep/wake complaint; 4) Simultaneously meeting the symptoms of items 1), 2), and 3), and persisting for more than 3 months and occurring at least 3 times a week (chronic insomnia) or =18 years old, gender not limited; 5.There were no language communication barriers, and the research participants could accurately understand the content of the questionnaire; 6.By agreeing to participate in this study, you can cooperate with the visit and sign the informed consent form;

Exclusion criteria

Exclusion criteria: 1. Large amounts of serous cavity effusions, including pleural effusion, peritoneal effusion, and pericardial effusion, require drainage to relieve compression symptoms; 2. Ongoing research on other weakly alkaline negative potential monomolecular high-activity water; 3. Pregnant or lactating women; 4. Patients with abnormal cardiac function indicators, abnormal renal function indicators, etc., such as BNP > 100pg/ml, NT-BNP > 300pg/ml, GFR < 60ml/min/1.73m^2, etc. 5. Poor compliance, low educational level, or those who cannot understand the content of the scale after repeated explanations.

Design outcomes

Primary

MeasureTime frame
Fatigue, insomnia, constipation;Comorbidity Improvement Rate (blood pressure, blood glucose, uric acid, fatigue, insomnia, constipat;

Secondary

MeasureTime frame
Blood lipids, blood routine;Inflammatory markers, immune markers;Liver function, kidney function, electrolytes;Quality of Life Scale Score;

Countries

China

Contacts

Public ContactFang Fengqi

The First Affiliated Hospital of Dalian Medical University

ffqlj@163.com+86 411 83635963

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 23, 2026